公开(公告)号：US20230331705A1

公开(公告)日：2023-10-19

申请号：US17999254

申请日：2021-05-19

Applicant: Senda Biosciences, Inc.

Inventor： Alessandra Bartolozzi ,  John Robert Proudfoot ,  Timothy Briggs ,  John Mancuso ,  Maxence Bos ,  Vu Linh Ly ,  Anna Blois ,  Bernard Lanter ,  Steven John Taylor ,  Leonard Buckbinder

IPC: C07D403/12 ,  A61K45/06 ,  C07D235/18 ,  A61P35/04

CPC classification number: C07D403/12 ,  A61K45/06 ,  C07D235/18 ,  A61P35/04

Abstract: The present disclosure relates to compounds of formulae (I)-(VI) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.

公开(公告)号：US20230181493A1

公开(公告)日：2023-06-15

申请号：US17995749

申请日：2021-04-09

Applicant: SENDA BIOSCIENCES, INC.

Inventor： Devin Forest Reed DOUD ,  Afrand KAMALI ,  Victoria CATANZANO ,  Yohannes TEFFERA ,  Spencer Cory PECK ,  William McELROY ,  Timothy F. BRIGGS ,  Steven John TAYLOR

IPC: A61K31/137 ,  G01N33/68 ,  A61P25/16

CPC classification number: A61K31/137 ,  G01N33/6896 ,  A61P25/16 ,  G01N2800/52

Abstract: The present disclosure relates to the treatment of Parkinson's disease. The present disclosure provides, in some embodiments, methods of treating Parkinson's disease in a patient in need thereof. In some embodiments, the methods disclosed herein comprise administering a levodopa therapy based on a patient's biomarker profile. In some embodiments, the levodopa therapy comprises or lacks a tyrosine decarboxylase inhibitor. Therapeutic uses and compositions are also disclosed.

公开(公告)号：US20230381182A1

公开(公告)日：2023-11-30

申请号：US18248123

申请日：2021-10-13

Applicant: Senda Biosciences, Inc.

Inventor： Devin Forest Reed Doud ,  Francesca Barone ,  Mark Umbarger

IPC: A61K31/519 ,  G01N33/574 ,  G01N33/68 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/519 ,  G01N33/57484 ,  G01N33/6851 ,  G01N33/6812 ,  A61K39/3955 ,  A61P35/00 ,  G01N2500/10

Abstract: The disclosure relates to biomarkers predictive of a patient's cancer responsiveness to an immune checkpoint inhibitor therapy. The disclosure provides, in some embodiments, diagnostic and/or prognostic methods of using such biomarkers for determining whether a cancer patient would benefit from being treated with an aryl hydrocarbon receptor antagonist. In some embodiments, the biomarkers described herein may be used to inform and provide effective therapeutic methods for treating cancer comprising administering an aryl hydrocarbon receptor antagonist, optionally in combination with an immune checkpoint inhibitor therapy.

公开(公告)号：US20230234967A1

公开(公告)日：2023-07-27

申请号：US17999443

申请日：2021-05-27

Applicant: Senda Biosciences, Inc.

Inventor： Alessandra Bartolozzi ,  John Robert Proudfoot ,  Timothy Briggs ,  John Mancuso ,  Maxence Bos ,  Tianlin Guo ,  Vu Linh Ly ,  Anna Blois ,  Bernard Lanter ,  Steven John Taylor ,  Leonard Buckbinder

IPC: C07D513/04 ,  C07D498/04 ,  C07D471/04 ,  C07D487/04 ,  A61P35/00 ,  A61P1/00 ,  A61K39/395 ,  A61K31/437 ,  A61K31/444 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/519 ,  A61K31/4985

CPC classification number: C07D513/04 ,  C07D498/04 ,  C07D471/04 ,  C07D487/04 ,  A61P35/00 ,  A61P1/00 ,  A61K39/3955 ,  A61K31/437 ,  A61K31/444 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/519 ,  A61K31/4985

Abstract: The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.

公开(公告)号：US20230234917A1

公开(公告)日：2023-07-27

申请号：US18001238

申请日：2021-06-09

Applicant: SENDA BIOSCIENCES, INC.

Inventor： Spencer Cory PECK ,  Jenny LIU ,  Timothy F. BRIGGS ,  John Robert PROUDFOOT ,  William MCELROY ,  Robert Walter MYERS ,  Steven John TAYLOR

IPC: C07C237/10 ,  A61P35/00 ,  C07K5/062 ,  C07D305/08 ,  C07C275/14 ,  C07C271/20 ,  C07F9/40 ,  C07F9/42 ,  C07C317/08 ,  C07F5/02 ,  C07C237/22 ,  C07D263/32 ,  C07D233/64 ,  C07D257/04 ,  C07D249/08 ,  C07D271/06 ,  C07D271/10 ,  C07D249/04 ,  C07C255/29 ,  C07D213/40 ,  C07D333/20 ,  C07D235/16

CPC classification number: C07C237/10 ,  A61P35/00 ,  C07K5/06026 ,  C07D305/08 ,  C07C275/14 ,  C07C271/20 ,  C07F9/4006 ,  C07F9/425 ,  C07C317/08 ,  C07F5/027 ,  C07C237/22 ,  C07D263/32 ,  C07D233/64 ,  C07D257/04 ,  C07D249/08 ,  C07D271/06 ,  C07D271/10 ,  C07D249/04 ,  C07C255/29 ,  C07D213/40 ,  C07D333/20 ,  C07D235/16 ,  C07C2601/14

Abstract: The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.

公开(公告)号：US20230295152A1

公开(公告)日：2023-09-21

申请号：US17756243

申请日：2020-11-20

Applicant: SENDA BIOSCIENCES, INC.

Inventor： Alessandra BARTOLOZZI ,  John Robert PROUDFOOT ,  Timothy BRIGGS ,  John MANCUSO ,  Karunakar Reddy BONEPALLY ,  Patrick BUREAU ,  Tianlin GUO ,  Maxence BOS ,  Anna BLOIS ,  Bernard LANTER ,  Steven John TAYLOR ,  Leonard BUCKBINDER ,  Francesca BARONE

IPC: C07D471/04 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00

Abstract: The present disclosure relates to compounds of formula (Ia) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling. These compounds may also be useful in treating cancer when administered in combination with at least one additional therapy.